FDA inspection
Celgene Corporation: FDA inspection ending Jan 25, 2017
FDA inspection 1000482 · Summit, NJ
Key facts
| Inspection ID | 1000482 |
|---|---|
| Firm | Celgene Corporation |
| FEI number | 3004991673 |
| Address | 556 Morris Ave Bldg S6 |
| City | Summit |
| State | NJ |
| ZIP | 07901-1330 |
| Fiscal year | 2017 |
| Inspection end date | Jan 25, 2017 |
| Project area | Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs|Postmarketing Surveillance and Epidemiology: Human Drugs |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data